These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29700947)

  • 1. Fetal RHD genotyping is a cost-effective option for supporting targeted anti-D prophylaxis in D-negative pregnancies.
    Allard S; Massey E
    BJOG; 2018 Oct; 125(11):1423. PubMed ID: 29700947
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of noninvasive fetal RhD blood group genotyping in nonalloimmunized and alloimmunized pregnancies.
    Gajic-Veljanoski O; Li C; Schaink AK; Guo J; Shehata N; Charames GS; de Vrijer B; Clarke G; Pechlivanoglou P; Okun N; Kandel R; Dooley J; Higgins C; Ng V; Sikich N
    Transfusion; 2022 May; 62(5):1089-1102. PubMed ID: 35170037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs and benefits of non-invasive fetal RhD determination.
    Teitelbaum L; Metcalfe A; Clarke G; Parboosingh JS; Wilson RD; Johnson JM
    Ultrasound Obstet Gynecol; 2015 Jan; 45(1):84-8. PubMed ID: 25380024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis.
    Neovius M; Tiblad E; Westgren M; Kublickas M; Neovius K; Wikman A
    BJOG; 2016 Jul; 123(8):1337-46. PubMed ID: 26663771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and costs of non-invasive foetal RHD genotyping in rhesus-D negative mothers: a French multicentric two-arm study of 850 women.
    Darlington M; Carbonne B; Mailloux A; Brossard Y; Levy-Mozziconacci A; Cortey A; Maoulida H; Simon T; Rousseau A; Durand-Zaleski I;
    BMC Pregnancy Childbirth; 2018 Dec; 18(1):496. PubMed ID: 30547830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is the management of Rh-Rh incompatibility with noninvasive fetal Rh genotyping for targeted prophylaxis cost-effective in the Turkish population?
    Demirel E; Kelekçi S; Ekmekci E; Şengül M; İri R; Atasever M
    Turk J Med Sci; 2018 Feb; 48(1):1-4. PubMed ID: 29479934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis.
    Hawk AF; Chang EY; Shields SM; Simpson KN
    Obstet Gynecol; 2013 Sep; 122(3):579-85. PubMed ID: 23921866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fetal RHD typing: Is fetal RHD typing in all RhD negative women cost effective?
    Szczepura A; Bonsel G; Krauth C; Osipenko L; Haverkamp A
    BMJ; 2008 Apr; 336(7650):906. PubMed ID: 18436926
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeted routine antenatal anti-D prophylaxis in the prevention of RhD immunisation--outcome of a new antenatal screening and prevention program.
    Tiblad E; Taune Wikman A; Ajne G; Blanck A; Jansson Y; Karlsson A; Nordlander E; Holländer BS; Westgren M
    PLoS One; 2013; 8(8):e70984. PubMed ID: 23940682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new fetal RHD genotyping test: costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales.
    Szczepura A; Osipenko L; Freeman K
    BMC Pregnancy Childbirth; 2011 Jan; 11():5. PubMed ID: 21244652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninvasive fetal RHD genotyping to guide targeted anti-D prophylaxis-an external quality assessment workshop.
    Clausen FB; Barrett AN;
    Vox Sang; 2019 May; 114(4):386-393. PubMed ID: 30834546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive Fetal RhD Blood Group Genotyping: A Systematic Review of Economic Evaluations.
    Gajic-Veljanoski O; Li C; Schaink AK; Guo J; Higgins C; Shehata N; Okun N; de Vrijer B; Pechlivanoglou P; Ng V; Sikich N
    J Obstet Gynaecol Can; 2021 Dec; 43(12):1416-1425.e5. PubMed ID: 34390866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No. 343-Routine Non-invasive Prenatal Prediction of Fetal RHD Genotype in Canada: The Time is Here.
    Johnson JA; MacDonald K; Clarke G; Skoll A
    J Obstet Gynaecol Can; 2017 May; 39(5):366-373. PubMed ID: 28454757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative.
    Chilcott J; Tappenden P; Lloyd Jones M; Wight J; Forman K; Wray J; Beverley C
    BJOG; 2004 Sep; 111(9):903-7. PubMed ID: 15327602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-throughput, non-invasive prenatal testing for fetal Rhesus D genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis.
    Saramago P; Yang H; Llewellyn A; Palmer S; Simmonds M; Griffin S
    BJOG; 2018 Oct; 125(11):1414-1422. PubMed ID: 29415334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted antenatal anti-D prophylaxis program for RhD-negative pregnant women - outcome of the first two years of a national program in Finland.
    Haimila K; Sulin K; Kuosmanen M; Sareneva I; Korhonen A; Natunen S; Tuimala J; Sainio S
    Acta Obstet Gynecol Scand; 2017 Oct; 96(10):1228-1233. PubMed ID: 28718198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of the management of rh-negative pregnant women.
    Duplantie J; Gonzales OM; Bois A; Nshimyumukiza L; Gekas J; Bujold E; Morin V; Vallée M; Giguère Y; Gagné C; Rousseau F; Reinharz D
    J Obstet Gynaecol Can; 2013 Aug; 35(8):730-740. PubMed ID: 24007709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Norwegian experience with nationwide implementation of fetal RHD genotyping and targeted routine antenatal anti-D prophylaxis.
    Sørensen K; Baevre MS; Tomter G; Llohn AH; Hagen KG; Espinosa A; Jacobsen B; Arsenovic MG; Sørvoll IH; Ulvahaug AN; Sundic T; Akkök ÇA
    Transfus Med; 2021 Oct; 31(5):314-321. PubMed ID: 33821537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prevention of fetomaternal rhesus-D allo-immunization. Practical aspects].
    Cortey A; Brossard Y
    J Gynecol Obstet Biol Reprod (Paris); 2006 Feb; 35(1 Suppl):1S123-1S130. PubMed ID: 16495838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted antenatal anti-D prophylaxis for RhD-negative pregnant women: a systematic review.
    Runkel B; Bein G; Sieben W; Sow D; Polus S; Fleer D
    BMC Pregnancy Childbirth; 2020 Feb; 20(1):83. PubMed ID: 32033599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.